Suppr超能文献

乳房缩小术引流管:不建议使用引流管的推荐有多好?

Drains in Breast Reduction: How Good Is the Recommendation Not to Use Them?

出版信息

Aesthet Surg J. 2024 Oct 15;44(11):1179-1185. doi: 10.1093/asj/sjae116.

Abstract

A clinical practice guideline (CPG) from the American Society of Plastic Surgeons recommended not to use drains in breast reduction. This CPG was based on 3 randomized controlled trials (RCTs). The objective of this review was to double-check the methodological quality of the 3 RCTs. These RCTs were critically appraised using: (1) the "User's Guide to the Surgical Literature" checklist to critically appraise the methodological quality, (2) the CONSORT guidelines for reporting quality, and (3) the Cochrane risk-of-bias tool 2 (RoB 2) for risk of bias. Weaknesses were identified in all assessments for the 3 RCTs. Items with the poorest adherence in the "User's Guide" included: "Were patients stratified?," "Was follow-up complete?," and "Were all clinically important outcomes considered?" The overall adherence to the CONSORT reporting checklist across all 3 studies was moderate with 40.0%, 62.1%, and 48.3% adherence. All 3 RCTs had a similar low to moderate risk of bias, with no areas with a high risk of bias. None of the studies took into consideration a single critical outcome (such as major hematoma) and the outcome's minimally important difference as the basis for the sample size and power calculation of the study. All 3 RCTs additionally lacked clear reporting of treatment effect sizes or precision of estimates. Our re-examination of the evidence questions the recommendation of the CPG. We believe that the recommendation should have been: "We remain uncertain whether drains in breast reduction have a salutary effect." As such, we recommend that a methodologically robust RCT be conducted to resolve the question of whether drains should be used in breast reduction.

摘要

美国整形外科学会的临床实践指南(CPG)建议在乳房缩小术中不使用引流管。该 CPG 基于 3 项随机对照试验(RCT)。本综述的目的是双重检查这 3 项 RCT 的方法学质量。这些 RCT 使用以下方法进行严格评估:(1)“外科文献使用指南”检查表,以严格评估方法学质量,(2)CONSORT 报告质量指南,以及(3)Cochrane 偏倚风险工具 2(RoB 2)用于评估偏倚风险。这 3 项 RCT 在所有评估中均存在缺陷。“使用指南”中最不遵守的项目包括:“患者是否分层?”、“随访是否完整?”以及“是否考虑了所有临床重要结局?”这 3 项研究的 CONSORT 报告清单的总体遵守率中等,分别为 40.0%、62.1%和 48.3%。这 3 项 RCT 均具有相似的低至中度偏倚风险,没有高偏倚风险的领域。没有一项研究将单一关键结局(如大出血)及其最小临床重要差异作为研究样本量和效力计算的依据。这 3 项 RCT 还缺乏对治疗效果大小或估计精度的明确报告。我们对证据的重新审查对 CPG 的建议提出了质疑。我们认为,该建议本应是:“我们仍然不确定乳房缩小术中使用引流管是否有益。”因此,我们建议进行一项方法学上稳健的 RCT,以解决在乳房缩小术中是否应使用引流管的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d51b/11474604/6bcb68f973de/sjae116f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验